← back to search

Laura Videla

Biomedical Research Institute ·
Area of research
Public Health, Environmental and Occupational Health · Psychiatry and Mental health
Research interest
Research interests include Down syndrome and intellectual disability research, Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, and Genetic Neurodegenerative Diseases.
h-index
26
citations
2,872
works
130
NIH funding
primary concept
Medicine
email

Recent publications

Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease
Alzheimer s & Dementia 2025cited by 13position: middledoi
Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease Stages
Neurology 2025cited by 11position: middledoi
Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimer´s disease
Nature Communications 2025cited by 9position: middledoi
APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease
Nature Medicine 2024cited by 311position: middledoi
Association of biological sex with clinical outcomes and biomarkers of Alzheimer’s disease in adults with Down syndrome
Brain Communications 2023cited by 60position: middledoi
Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study
EBioMedicine 2023cited by 55position: middledoi
Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome
Alzheimer s & Dementia 2023cited by 30position: middledoi
Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome
JAMA Neurology 2021cited by 78position: middledoi
Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
Nature Communications 2021cited by 71position: middledoi
Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias
Journal of Neurology Neurosurgery & Psychiatry 2021cited by 67position: middledoi
Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study
The Lancet Neurology 2021cited by 62position: middledoi
Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
The Lancet Neurology 2018cited by 211position: middledoi
Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal‐dominant Alzheimer's disease
Alzheimer s & Dementia 2017cited by 88position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Daniel Alcolea · Hospital de Sant Pau5 papers (2017–2025)Juan Fortea · Hospital de Sant Pau5 papers (2017–2025)Alberto Lleó · Instituto de Salud Carlos III5 papers (2017–2025)María Carmona‐Iragui · Hospital de Sant Pau4 papers (2017–2025)Isabel Barroeta · Instituto de Salud Carlos III3 papers (2018–2025)Rafael Blesa · Universitat Autònoma de Barcelona3 papers (2017–2021)Bessy Benejam · Universitat Autònoma de Barcelona3 papers (2017–2025)Jordi Pegueroles · Barcelona Institute for Global Health2 papers (2018–2024)Elizabeth Head · University of California, Irvine2 papers (2017–2021)Susana Fernández · Hospital de Sant Joan Despí Moisès Broggi2 papers (2017–2018)Sebastián Videla · Institut Català d'Oncologia2 papers (2017–2018)Olivia Belbin · Hospital de Sant Pau2 papers (2018–2024)Laia Muñoz · Universitat Autònoma de Barcelona2 papers (2018–2021)Frederick A. Schmitt · University of Kentucky2 papers (2017–2021)Jordi Clarimón · Hospital de Sant Pau2 papers (2017–2018)José Luís Molinuevo · Lundbeck (Denmark)1 papers (2017–2017)Fernando González‐Ortiz · Sahlgrenska University Hospital1 papers (2025–2025)Lisa Koehl · University of Kentucky1 papers (2021–2021)Mircea Balasa · Centro de Investigación Biomédica en Red1 papers (2017–2017) · 1 papers (2018–2018)